Covered recipient · General Payments record
NICHOLAS PAUL SCAPINI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2022–2025
$2,385.01
- Reported across 66 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $460.47 | 17 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Axsome Therapeutics, Inc. | $117.50 | 1 |
| UCB, Inc. | $69.99 | 4 |
| TG THERAPEUTICS, INC. | $51.48 | 2 |
| Biogen, Inc. | $47.96 | 2 |
| ABBVIE INC. | $41.11 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.63 | 1 |
| Alexion Pharmaceuticals, Inc. | $22.95 | 1 |
| EISAI INC. | $22.17 | 1 |
| JAZZ PHARMACEUTICALS INC. | $21.97 | 1 |
| Genentech USA, Inc. | $21.62 | 1 |
| Lilly USA, LLC | $15.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.03 | 03/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204087334 | CMS |
| ABBVIE INC. | $22.08 | 04/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204087342 | CMS |
| Alexion Pharmaceuticals, Inc. | $22.95 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202920812 | CMS |
| Axsome Therapeutics, Inc. | $117.50 | 10/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235778748 | CMS |
| Biogen, Inc. | $24.17 | 09/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208453814 | CMS |
| Biogen, Inc. | $23.79 | 12/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208348250 | CMS |
| Eisai Inc. | $22.17 | 02/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244502574 | CMS |
| Genentech USA, Inc. | $21.62 | 03/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1211560072 | CMS |
| JAZZ PHARMACEUTICALS INC. | $21.97 | 04/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234334037 | CMS |
| Lilly USA, LLC | $15.09 | 01/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186757551 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.63 | 04/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1223915370 | CMS |
| TG Therapeutics, Inc. | $27.38 | 04/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1226237305 | CMS |
| TG Therapeutics, Inc. | $24.10 | 08/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1226237454 | CMS |
| UCB, Inc. | $18.43 | 04/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224784096 | CMS |
| UCB, Inc. | $14.67 | 06/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224784098 | CMS |
| UCB, Inc. | $15.28 | 07/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224784100 | CMS |
| UCB, Inc. | $21.61 | 10/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224784102 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.